Indonesia's food and drug authority BPOM has issued an emergency use authorisation (EUA) for the Covid-19 vaccine produced by Chinese pharmaceutical company Sinopharm, an official source said on Friday.
Chief of BPOM Penny Lukito made the announcement, saying the issuance of the EUA was based on the third phase of clinical trials in the United Arab Emirates and other countries, the Xinhua news agency reported.
Indonesia would use the Sinopharm vaccine for a mutual vaccination scheme locally known as "Gotong Royong", where companies or legal entities can arrange the Covid-19 vaccine rollout for their employees for free, to help the country achieve herd immunity faster.
Previously, Indonesia had approved the emergency use for three other brands of Covid-19 vaccines, namely the CoronaVac produced by the Chinese company Sinovac, the Covid-19 vaccine produced by the state-company PT Bio Farma in collaboration with Sinovac, and the AstraZeneca vaccine.
he Chinese Coronavirus vaccine, developed by Sinopharm, has been approved for emergency use in a few countries, while the company is still conducting late-stage trials in 10 nations. The vaccine relied on technology, using a killed virus to deliver the shot—a similar concept used to create polio immunizations. In UAE, some of the top officials, including Dubai's ruler Sheikh Mohammed bin Rashid Al Maktoum, have publicly received the Chinese vaccine.
The other vaccine developers like Pfizer and its German partner BioNTech use newer and less-proven technology to target the virus' spike protein using RNA.
(With inputs from IANS)
